QURE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the provided data, uniQure (QURE) is not a strong buy for a beginner, long-term investor at this time. While there are some positive regulatory developments and analyst upgrades, the financial performance, ongoing lawsuits, and regulatory uncertainty weigh heavily against a decisive buy recommendation. A 'hold' is recommended to wait for further clarity on regulatory outcomes and financial improvements.
The MACD is above 0 and positively contracting, indicating mild bullish momentum. RSI is neutral at 51.392, suggesting no strong overbought or oversold conditions. Moving averages are converging, and the stock is trading near its pivot point of 16.079, with resistance at 17.984 and support at 14.175. Overall, the technical indicators suggest a neutral to slightly bullish trend.
Analysts like H.C. Wainwright and Wells Fargo have reiterated strong buy ratings with significantly increased price targets. The company's gross margin has improved YoY, indicating operational efficiency.
The company is facing multiple class action lawsuits, alleging false statements regarding FDA approval. Regulatory uncertainty remains high, with the FDA requiring a Phase 3 trial for AMT-130, which could delay approval by several years. Financial performance has deteriorated significantly, with net income and EPS dropping sharply YoY.
In Q4 2025, revenue increased by 6.65% YoY to $5,568,000, but net income dropped by 49.38% YoY to -$37,086,000. EPS fell by 60.67% YoY to -0.59. Gross margin improved to 92.19%, up 4.59% YoY. While revenue and gross margin show growth, the steep decline in net income and EPS highlights financial struggles.
Analyst sentiment is mixed but leans positive. Recent upgrades from firms like Mizuho, Wells Fargo, and RBC Capital suggest optimism about regulatory changes and the potential approval of AMT-130. However, Barclays and Chardan have expressed concerns about regulatory uncertainty and the need for a Phase 3 trial, leading to lower price targets.
